Investigator

Simone Morra

Consultant · Azienda Ospedaliera Universitaria Federico II, Urology Department- Urologic Oncology and Minimally invasive Surgery

About

SMSimone Morra
Papers(1)
Synchronous Ovarian S…
Collaborators(6)
Annamaria ColaoDaniela TerraccianoGiovanni SavareseMario AscioneNicola LongoPaolo Emidio Macchia
Institutions(2)
University Of Naples …Centro AMES

Papers

Synchronous Ovarian Sertoli–Leydig Cell and Clear Cell Papillary Renal Cell Tumors: A Rare Case Without Mutations in Cancer-Associated Genes

(1) Background: Sertoli–Leydig cell tumors (SLCTs) are rare ovarian neoplasms that account for less than 0.5% of all ovarian tumors. They usually affect young women and often present with androgenic symptoms. We report a unique case of a 40-year-old woman diagnosed with both SLCT and clear cell papillary renal cell carcinoma (CCP-RCC), a rare tumor association with unclear pathogenesis. (2) Methods: Both tumors were treated surgically. The diagnostic workup included hormonal testing, imaging studies, and extensive genetic testing, including DICER1 mutation analysis and multiplex ligation-dependent probe amplification (MLPA), as well as the examination of a next-generation sequencing (NGS) panel covering ~280 cancer-related genes. (3) Results: Histopathologic examination confirmed a well-differentiated SLCT and CCP-RCC. No pathogenic variants in DICER1 were identified by WES or MLPA. No clinically relevant changes were found in the extended NGS panel either, so a known hereditary predisposition could be ruled out. The synchronous occurrence of both tumors without genomic alterations could indicate a sporadic event or as yet unidentified mechanisms. (4) Conclusions: This case highlights the importance of a multidisciplinary approach in the management of rare tumor compounds. The exclusion of DICER1 mutations and the absence of genetic findings adds new evidence to the limited literature and underscores the importance of long-term surveillance and further research into potential shared oncogenic pathways.

122Works
1Papers
6Collaborators
Prostatic NeoplasmsNeoplasm StagingNeoplasm GradingKidney NeoplasmsNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsPrognosisCystitis, Interstitial

Positions

2024–

Consultant

Azienda Ospedaliera Universitaria Federico II · Urology Department- Urologic Oncology and Minimally invasive Surgery

2019–

Resident

Università degli Studi di Napoli Federico II Dipartimento di Medicina Clinica e Chirurgia · Urology

2023–

Clinical Fellow

Onze Lieve Vrouwziekenhuis Hospital · Urology

2023–

Research and Clinical Fellow

ORSI Academy · Urology

2022–

Research Fellow

Fondation du CHUM · Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center

Education

2024

Specialization in Urology

Università degli Studi di Napoli Federico II · Urology

2018

Master Degree

Università degli Studi di Napoli Federico II Dipartimento di Medicina Clinica e Chirurgia

Country

IT

Keywords
UrologyOncologyKidney cancerProstate cancerBladder cancerLUTS
Links & IDs
0000-0001-5340-8569

Scopus: 57573543500